Daniel Reef
YOU?
Author Swipe
View article: Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?
Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world? Open
Introduction: Older adults (OAs) with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients (pts). NAVD has been widely adopted in clinical practice for frontline (1L) treatment of OAs with advanced stage cHL…
View article: A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study
A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study Open
Introduction: NAVD has become a standard-of-care for frontline (1L) treatment (tx) of advanced stage cHL, based on the results of the S1826 study. S1826 demonstrated a 1-year progression free survival (PFS) of 94% for NAVD compared to 86% …
View article: Infections in patients with aggressive B-cell lymphomas treated with CD3xCD20 bispecific antibodies
Infections in patients with aggressive B-cell lymphomas treated with CD3xCD20 bispecific antibodies Open
Introduction CD3xCD20 bispecific antibodies (BsAbs) can provide durable responses for patients with aggressive B-cell lymphomas. However, they can cause toxicity, including cytokine release syndrome, neurotoxicity, cytopenias, and infectio…
View article: Long term follow up autologous CD30.CAR-T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy
Long term follow up autologous CD30.CAR-T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy Open
Sairah Ahmed1*, Matthew Mei2* *co-first authors Introduction Classical Hodgkin lymphoma (cHL) is characterized by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells, which harbor amplifications in chromosome 9p24.1, leading to ov…
View article: Population-Level Outcomes in Solitary Plasmacytoma: A Surveillance, Epidemiology, and End Results (SEER) Study
Population-Level Outcomes in Solitary Plasmacytoma: A Surveillance, Epidemiology, and End Results (SEER) Study Open
Introduction Solitary plasmacytoma (SP) is a plasma cell dyscrasia characterized by a single tumor consisting of clonal plasma cells. Typical management involves local therapy, usually with a definitive course of radiation therapy (RT), le…
View article: Phase 1 Trial of CD30-Directed, CCR4 Co-Expressing Chimeric Antigen Receptor T-Cells in Patients with CD30+ Cutaneous T-Cell Lymphomas Refractory to Brentuximab Vedotin
Phase 1 Trial of CD30-Directed, CCR4 Co-Expressing Chimeric Antigen Receptor T-Cells in Patients with CD30+ Cutaneous T-Cell Lymphomas Refractory to Brentuximab Vedotin Open
Background CD30 CAR-T (CD30.CART) has shown activity in CD30+ lymphomas, including T-cell lymphomas (TCLs) and Hodgkin lymphoma (HL). We conducted a phase 1 trial in patients (pts) with cutaneous TCL (CTCL) and HL to study CD30.CART modifi…
View article: Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma
Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma Open
Adult T-cell leukemia/lymphoma (ATLL) remains challenging to treat and has dismal outcome. Allogeneic stem-cell transplantation (allo-SCT) has promising results, but data remain scarce. In this single-center retrospective analysis of 100 p…